Palbociclib Regimen Yields ‘Incredible’ PFS Gain in Metastatic Breast Cancer
SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy resulted in a significant and ...
Day: December 12, 2024
Growing Price Tag Reported for Newer De Facto Stroke Lytic
NEW ORLEANS -- Tenecteplase in recent years outpaced alteplase as the stroke thrombolytic of choice at one large hospital system, ...
Experts Weigh Benefits of Drug Price Negotiation and Other Price-Curbing Strategies
Policy experts punched holes in drug companies' claims that the Medicare Drug Price Negotiation Program will stunt innovation and weighed ...
MedPAC Members Supportive of Upping Medicare Pay Rates Close to the Inflation Rate
Members of the Medicare Payment Advisory Commission (MedPAC) seemed favorable Thursday to a proposed recommendation to Congress that Medicare should ...
Trump Nearly Backed 16-Week Federal Abortion Ban
Donald Trump was on the verge of backing a 16-week federal abortion ban earlier this year when aides staged an ...
MD Reacts to Anesthesia Policy; Debunking Pedialyte Misinfo; Passion vs Practicality
The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. "Babe, wake up, your surgery ...
Jamie Foxx’s Stroke: Here’s What to Know
Actor, comedian, and singer Jamie Foxx revealed that his mystery ailment last year was a brain bleed and stroke. In ...
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast Cancer
SAN ANTONIO -- Carriers of germline BRCA mutations diagnosed with breast cancer by age 40 who underwent risk-reducing surgeries had ...
Skip Surgery for DCIS in Favor of Active Monitoring?
SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ...
Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk Patients
The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related cardiovascular (CV) events ...
New Investigation Casts Doubt on Landmark Ticagrelor Trial
New questions about the landmark trial that launched the antiplatelet drug ticagrelor worldwide are being raised after an investigation uncovered ...
Doc Confesses to Killing Wife, Police Say; Nurse Reprimanded for Cursing at Toddler
Orlando-area physician Thomas Wentzell, MD, was arrested and confessed to killing his wife, according to local police. (WFTV9) Twenty lawsuits ...
The 7 Biggest Financial Enemies of Doctors
Success in personal finance and reaching financial freedom is not complicated. But that does not mean it is necessarily easy ...
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
One of the most meaningful shifts in the cancer treatment landscape has been the move toward therapies that not only ...
Benefits and Risks of the Viral Workout
Share on PinterestThe 12-3-30 treadmill challenge is trending on TikTok, but can the viral workout really help you lose weight? ...
FDA Issues Safety Alert on Liver Disease Drug
Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without ...
Are Schools Shifting From Drug Prevention to Mental Health?
TOPLINE:From 2008 to 2020, US schools reported significant increases in emotional/mental health education (from 83.8% to 89.8%) and suicide prevention ...
Providers, You Are the Missing Piece: Your Patients With OUD Need You
Califf is FDA commissioner. Sokolowska is an FDA deputy center director specializing in substance use and behavioral health. As of ...
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer
The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as ...
First final compensation in blood scandal to be paid in days
The government has said the first victims of the infected blood scandal will receive final compensation payments this week. Ten ...
